about
Genelux Corp is a late-stage biopharmaceutical firm focused on developing oncolytic viral immunotherapies for cancer. Its pipeline includes clinical and preclinical candidates designed to target tumor cells and stimulate an immune response against tu...
Read More
2.87
0.05
(1.77%)
50,178.2
XNAS Volume
XNAS 17 Jul, 2026 1:53 PM (EDT)
Not Eligible
Expensive Valuation
Technically Bearish
Genelux Corp Live Price Chart
Switch to TradingView
Loading Fundamental data..
Loading data..